WuXi Biologics Reports Strong Profitable Growth in H1 2026
- Written by PR Newswire
- Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD)
- IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds
- EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY; adjusted EBITDA grew 24.9% and adjusted net profit rose 38.6% YoY
- Earnings...
